Chemo and radiation for advanced nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests whether a specific chemotherapy drug (nab-paclitaxel) given along with targeted radiation therapy can help people with stage III or IVa nasopharyngeal cancer. The goal is to improve treatment outcomes while managing side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with nasopharyngeal cancer (a type of head and neck cancer).
- Your cancer is stage III or IVa (advanced but not spread to distant organs).
- You are between 18 and 70 years old.
- You are in good enough health to tolerate chemotherapy and radiation (your doctor calls this PS 0-1).
- Your major organs (heart, liver, kidneys, bone marrow) are working well enough for treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (toripalimab), chemotherapy, radiation, and omega-3 supplements for people with locally advanced nasopharyngeal cancer that hasn't spread. The goal is to see if this approach works better than standard treatment.
This trial tests whether a special analysis of blood markers and imaging scans can help doctors choose the best combination of chemotherapy and radiation for nasopharyngeal cancer. The goal is to improve outcomes by tailoring treatment to each patient's specific cancer characteristics.
This trial is testing whether a newer, more precise type of radiation (proton therapy) works better than standard radiation (IMRT) for people with advanced nasopharyngeal cancer. It also includes chemotherapy and immunotherapy to see if the combination can improve outcomes.
This trial tests a combination of high and low dose radiation plus an immunotherapy drug (PD-1 inhibitor) for people whose nasopharyngeal cancer has come back after previous treatment. The goal is to see if this approach can be more effective while reducing side effects.
This trial tests a more precise form of radiation therapy (adaptive radiotherapy) for nasopharyngeal cancer. It is designed for patients who have not yet had any treatment and whose cancer is limited to the head and neck area.
This trial tests if adding an immunotherapy drug (PD-1 inhibitor) after standard induction chemotherapy helps keep advanced nasopharyngeal cancer from coming back. It is for people who have completed 3 cycles of GP chemotherapy combined with a PD-1 inhibitor and have not had their cancer progress.
Hear when a new Nasopharyngeal Carcinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.